Delisting riskPopularity #4,400
Cellyan Biotechnology (HKPD)
Cross-border OTC pharmaceutical fulfillment and distribution for Mainland Chinese e-commerce.
$0.1166
vs last close−0.01 (−4.43%)
In millions of USD, except per-share figures
| In millions | Q2 FY24Sep 2023 | Q4 FY24Mar 2024 | Q2 FY25Sep 2024 | Q4 FY25Mar 2025 | Q2 FY26Sep 2025 | Q4 FY26Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 7 | 10 | 11 | 9 | 7 | 6 |
| Cost of revenue | 6 | 7 | 9 | 9 | 6 | 6 |
| Gross profit | 1 | 2 | 2 | 1 | 1 | 0 |
| 1 | 1 | 1 | 1 | 1 | 2 | |
| Selling, general & administrative | 1 | 1 | 1 | 1 | 1 | 2 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 0 | 1 | 1 | −1 | 0 | −1 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 0 | 1 | 1 | −1 | 0 | −1 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 0 | 1 | 1 | −1 | 0 | −1 |
| Net income | 0 | 1 | 1 | −1 | 0 | −1 |
| EPS, basic | $0.04 | $0.11 | $0.08 | −$0.08 | $0.01 | −$0.04 |
| EPS, diluted | $0.04 | $0.11 | $0.08 | −$0.08 | $0.01 | −$0.04 |
| Weighted average shares, basic | 7 | 10 | 10 | 10 | 11 | 36 |
| Weighted average shares, diluted | 7 | 10 | 10 | 10 | 11 | 36 |
| EBITDA | 0 | 1 | 1 | −1 | 0 | −1 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | 1 | 1 | −1 | 0 | −1 |